title: [Aspirin use in patients with atherosclerotic cardiovascular disease: the 2016 Chinese expert consensus statement].
abstract: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death and has the largest disease burden in China. Aspirin is the most promising agent for the prevention of ASCVD in such a large population for its easy availability and relative effectiveness, although its use in primary prevention is still a subject of debate. The joint task force has reviewed the current evidence of aspirin use in healthy population and in patients with stable coronary artery disease, acute coronary syndrome, transient ischemic attack, stroke and peripheral artery disease. The consensus statement provides a practical algorithm for identifying those at a high 10-year ASCVD risk, with more than or equal to 10%, who may benefit from aspirin use. Recommendations for aspirin use in primary and secondary prevention of ASCVD in Chinese, as well as its safety and "resistance" issues, are also stated.
mesh_terms: D054058:Acute Coronary Syndrome; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000517:prevention & control*; D016022:Case-Control Studies; D002681:China; D032921:Consensus; D003327:Coronary Disease; D006801:Humans; D002546:Ischemic Attack, Transient / Q000517:prevention & control; D058729:Peripheral Arterial Disease; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D055502:Secondary Prevention / Q000379:methods* / Q000706:statistics & numerical data*; D020521:Stroke / Q000188:drug therapy / Q000517:prevention & control; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin